P1, N=36, Recruiting, Boston Scientific Corporation | Trial completion date: Jun 2026 --> Jan 2027 | Trial primary completion date: Mar 2026 --> Jul 2026

5 days ago

Trial completion date • Trial primary completion date • First-in-human

TheraSphere (yttrium 90 microspheres)

10d

Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma (clinicaltrials.gov)

P=N/A, N=64, Not yet recruiting, University of California, San Francisco | Trial completion date: May 2028 --> Dec 2028 | Initiation date: Nov 2025 --> May 2026 | Trial primary completion date: May 2028 --> Dec 2028

10 days ago

Trial completion date • Trial initiation date • Trial primary completion date

TheraSphere (yttrium 90 microspheres)

13d

EMERALD-Y90: A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE (clinicaltrials.gov)

P2, N=56, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting

13 days ago

Enrollment closed

Avastin (bevacizumab) • Imfinzi (durvalumab) • TheraSphere (yttrium 90 microspheres)

19d

ArTisaN: TheraSphere Selective Internal Radiation Therapy (SIRT) as Treatment for Neuroendocrine Tumours With Liver Mets (clinicaltrials.gov)

P2, N=24, Completed, Imperial College London | Recruiting --> Completed

19 days ago

Trial completion

TheraSphere (yttrium 90 microspheres)

3ms

P2, N=60, Recruiting, AstraZeneca | N=100 --> 60

3 months ago

Enrollment change

Avastin (bevacizumab) • Imfinzi (durvalumab) • TheraSphere (yttrium 90 microspheres)

4ms

Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk (clinicaltrials.gov)

P2, N=84, Suspended, Northwestern University | Trial primary completion date: Jul 2025 --> Jul 2026

4 months ago

Trial primary completion date

Avastin (bevacizumab) • Tecentriq (atezolizumab) • TheraSphere (yttrium 90 microspheres)

5ms

Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov)

P2, N=30, Recruiting, University of Miami | Not yet recruiting --> Recruiting | Trial completion date: Aug 2030 --> Nov 2030 | Initiation date: Aug 2025 --> Nov 2025 | Trial primary completion date: Aug 2030 --> Nov 2030

5 months ago

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date

Stivarga (regorafenib) • TheraSphere (yttrium 90 microspheres)

5ms

ROWAN: TheraSphere With Durvalumab and Tremelimumab for HCC (clinicaltrials.gov)

P2, N=100, Active, not recruiting, Boston Scientific Corporation | Recruiting --> Active, not recruiting

5 months ago

Enrollment closed

Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • TheraSphere (yttrium 90 microspheres)

6ms

Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma (clinicaltrials.gov)

P=N/A, N=64, Not yet recruiting, University of California, San Francisco

6 months ago

New trial

TheraSphere (yttrium 90 microspheres)

9ms

FRONTIER: A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM (clinicaltrials.gov)

P1, N=36, Recruiting, Boston Scientific Corporation | Active, not recruiting --> Recruiting | N=12 --> 36 | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Dec 2024 --> Mar 2026

9 months ago

Enrollment open • Enrollment change • Trial completion date • Trial primary completion date

TheraSphere (yttrium 90 microspheres)

10ms

Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov)

P2, N=28, Not yet recruiting, University of Miami

10 months ago

New P2 trial

Stivarga (regorafenib) • TheraSphere (yttrium 90 microspheres)